Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection

Liver International

Volumn 27, Issue 7, 2007, Pages 954-959

  Sagir, Abdurrahman ^a   Heintges, Tobias ^a   Akyazi, Zübeyde ^a   Oette, Mark ^a   Erhardt, Andreas ^a   Häussinger, Dieter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Hepatitis C; IFN; Retherapy; Ribavirin

Indexed keywords

ALPHA INTERFERON A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTHRALGIA; ARTICLE; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; QUALITATIVE ANALYSIS; RELAPSE; RETREATMENT; RETROSPECTIVE STUDY; SEROLOGY; THROMBOCYTOPENIA; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT SELECTION; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 34547866504     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01508.x     Document Type: Article

References (21)

1. Heintges T, Wands J. Hepatitis C virus: Epidemiology and transmission. Hepatology 1997; 26: 521-6.
2. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT). Lancet 1998; 352: 1426-32.
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med 1998; 339: 1485-92.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing peginterferon alfa-2b to Interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
6. Shiffman ML. Management of interferon therapy nonresponders. Clin Liver Dis 2001; 5: 1025-43.
7. Abbas Z, Hamid SS, Tabassum S, Jafri W. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin. J Pak Med Assoc 2004; 54: 571-4.
8. Camma C, Giunta M, Chemello L, et al. Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data. European concerted action on viral hepatitis (EUROHEP). Hepatology 1999; 30: 801-7.
9. Davis GL. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl. 1): 49-55.
10. Chuang WL, Dai CY, Chen SC, et al. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver Int 2004; 24: 595-602.
11. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-7.
12. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453-62.
13. Weegink CJ, Sentjens RE, Beld MG, Dijkgraaf MG, Reesink HW. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: A two-arm randomized pilot study. J Viral Hepatol 2003; 10: 174-82.
14. Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130: 1098-106.
15. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23, discussion 947.
16. Dai CY, Chuang WL, Chang WY, et al. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin. Antiviral Res 2005; 67: 93-7.
17. Gerotto M, Dal Pero F, Sullivan DG, et al. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha. J Viral Hepatol 1999; 6: 367-72.
18. Granot E, Shouval D, Ashur Y. Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients. Mediators Inflamm 2001; 10: 253-8.
19. Hung CH, Lee CM, Lu SN, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepatol 2003; 10: 87-94.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
21. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.